Active pulmonary tuberculosis — treatment
drug-sensitive TB · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pulmonary TB is treated with combination antimycobacterial therapy to cure disease and prevent resistance and transmission. Standard drug-sensitive disease uses a 2-month intensive and 4-month continuation phase, with attention to infection control, adherence and drug toxicity.
Red flags
- Rifampicin resistance on molecular testing (treat as drug-resistant TB)
- Massive haemoptysis
- Drug-induced hepatitis (nausea, jaundice, transaminitis)
- Visual disturbance (ethambutol toxicity)
- Miliary spread or TB meningitis
Assessment
Differential diagnosis
- Community-acquired/necrotising pneumonia
- Lung cancer
- Non-tuberculous mycobacterial disease
- Fungal infection (aspergilloma, histoplasmosis)
- Sarcoidosis
- Vasculitis
Investigations
- Sputum smear microscopy, culture and rapid molecular testing (e.g. Xpert MTB/RIF) with rifampicin-resistance detection
- Chest X-ray / CT (upper-lobe cavitation, infiltrates)
- Drug-susceptibility testing
- HIV test, baseline LFTs, renal function, visual acuity/colour vision
- Contact tracing and screening
Management
- Confirm diagnosis with molecular testing and culture, and detect rifampicin resistance early
- Implement airborne infection control and notify public health
- Test for HIV and assess comorbidities and baseline organ function
- Start standard four-drug intensive-phase therapy (RIPE) while awaiting full susceptibilities
- Give pyridoxine with isoniazid to prevent neuropathy
- Support adherence (directly observed or video-observed therapy where indicated)
- Monitor clinical response and convert to two-drug continuation phase after the intensive phase
- Monitor for hepatotoxicity, visual changes and drug interactions throughout
- Repeat sputum to confirm culture conversion and guide duration
- Extend therapy for cavitary/slow-responding disease and manage any resistance via specialist pathways
Drugs & doses
Intensive phase (2 months): Isoniazid 5 mg/kg (max 300 mg) + Rifampicin 10 mg/kg (max 600 mg) + Pyrazinamide 25 mg/kg + Ethambutol 15 mg/kg, all PO once daily
Continuation phase (4 months): Isoniazid + Rifampicin once daily
Pyridoxine 25 mg PO once daily
Fixed-dose combination tablets dosed by weight band
Disposition
Notify public health; TB specialist service; isolation for smear-positive disease; directly/video-observed therapy where adherence is a concern.
Complications & pitfalls
- Drug-induced hepatitis
- Acquired drug resistance from non-adherence
- Haemoptysis / aspergilloma in residual cavities
- Respiratory failure and bronchiectasis
- Paradoxical reaction / IRIS in HIV co-infection
Exam pearls
- Never add a single drug to a failing regimen — it amplifies resistance
- Rifampicin turns secretions orange and strongly induces hepatic enzymes (contraception, warfarin, ARVs)
- Monitor for ethambutol-related optic neuritis with baseline and periodic vision checks
- In HIV, time antiretroviral initiation to balance TB therapy and IRIS risk
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.